Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) reported record financial results for the fourth quarter and full year ended December 31, 2024, signaling a period of significant growth and financial stability for the biopharmaceutical company. The company’s earnings call, held on March 2, 2026, highlighted substantial revenue increases across its key product lines and provided optimistic guidance for 2026. This positive performance marks a turning point for Xeris, achieving net income on a full-year basis for 2025 and eliminating concerns about its ability to self-fund its research and development pipeline. The focus on innovative therapies continues to drive expansion, with plans for further investment in phase 3 studies and commercial operations.
The company announced fourth quarter revenue of $85.8 million, a 43% increase compared to the same period in 2024. Full-year revenue reached $291.8 million, representing a 44% increase year-over-year. This growth was fueled by strong performance from its three commercial products: Recorlev, Gvoke, and Keveyis. Recorlev, used to treat adrenocortical insufficiency, saw revenue of $45.3 million in the fourth quarter and $139.3 million for the full year, exceeding 100% growth compared to 2024. Gvoke, an emergency treatment for severe hypoglycemia, generated $24.6 million in Q4 and $94.1 million for the year. Keveyis, indicated for the treatment of pseudohypoaldosteronism type 1, contributed $12.8 million in Q4 and $47.6 million for the full year.
Strong Margins and Increased Investment in R&D
Xeris Biopharma demonstrated robust financial health with a gross margin of 87% in the fourth quarter and 85% for the full year. However, the company is also strategically reinvesting in its future. Research and development (R&D) expenses increased by 22% year-over-year, reaching $7.9 million in Q4 and $31.2 million for the full year. Selling, general, and administrative (SG&A) expenses also rose, increasing by 12% to $47.5 million in Q4 and $182.4 million for the year. These increases reflect the company’s commitment to expanding its pipeline and commercial reach.
The company reported adjusted EBITDA of $25.1 million in Q4 and $59.4 million for the full year. Notably, Xeris Biopharma achieved net income on a full-year basis in 2025, a significant milestone indicating financial self-sustainability. This achievement allows the company to confidently pursue its strategic goals without relying on external funding.
Looking Ahead: 2026 Guidance and Expansion Plans
Xeris Biopharma provided optimistic revenue guidance for 2026, expecting revenue to fall between $375 million and $390 million, representing over 30% growth at the midpoint. To support this growth, the company plans to increase its investment in R&D by approximately $25 million, primarily to fund a phase 3 study of XP-8121. SG&A expenses are also projected to increase by roughly $45 million to support commercial expansion efforts.
The company’s focus on expanding its commercial footprint and advancing its pipeline is expected to drive continued growth in the coming years. The phase 3 study of XP-8121, if successful, could add a significant new product to Xeris Biopharma’s portfolio. The increased SG&A spending will support the launch and marketing of existing and future products.
Potential Risks Highlighted
Despite the positive outlook, GuruFocus, as reported on March 2, 2026, has identified four warning signs associated with XERS. The specifics of these warning signs were not detailed in the available information, and investors are advised to conduct their own due diligence. Investors can test their investment thesis using a discounted cash flow calculator, as suggested by GuruFocus. Xeris Biopharma’s full earnings release provides further details on the company’s financial performance.
The company’s success is tied to the continued adoption of its existing products and the successful development and commercialization of its pipeline candidates. Competition in the biopharmaceutical industry is intense, and Xeris Biopharma will need to continue to innovate and execute effectively to maintain its growth trajectory. The company’s ability to navigate these challenges will be crucial to its long-term success.
Disclaimer: I am a financial analyst-turned-journalist. This article is for informational purposes only and should not be considered financial advice. Investing in pharmaceutical companies involves risks, and investors should consult with a qualified financial advisor before making any investment decisions.
Xeris Biopharma will next provide updates on its progress during its first-quarter 2026 earnings call, the timing of which has not yet been announced. Investors and stakeholders are encouraged to monitor the company’s news releases page for future announcements and updates.
What are your thoughts on Xeris Biopharma’s recent performance? Share your insights and questions in the comments below.
Keep reading
